Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer Earnings Up, Life Sciences Revenues Decline

NEW YORK, April 24 - PerkinElmer reported today earnings of $2.3 million and a slight increase in revenues for the first quarter.


These earnings, which came to $.02 per share, contrasted with the company's net loss of $147.3 million, or $1.17 per share, for the same period last year, which was widened due to changes in accounting rules.


Total sales for the company totaled $358.4 million, compared to $346.3 million in the same period last year.   While revenues in the company's optoelectronics and analytical instruments areas grew, revenue declined in life sciences.


R&D expenses for the quarter came to $20.9 million, compared to $21.8 million for the year-ago quarter.


The company had a total of $129.8 million in cash and cash equivalents at the end of March, compared to $170.4 million on March 31, 2002.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more